Aridis Pharmaceuticals (ARDS) Stock Statistics & Valuation Metrics

Aridis Pharmaceuticals has a market cap or net worth of $4.46K. The enterprise value is $8.63.

Aridis Pharmaceuticals has 44,574,020 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aridis Pharmaceuticals’s return on equity (ROE) is 1.27 and return on invested capital (ROIC) is 172.72%.

The current PE Ratio of Aridis Pharmaceuticals is ―. Aridis Pharmaceuticals’s PEG ratio is 0.01.

In the last 12 months, Aridis Pharmaceuticals had revenue of 0.00 and earned -30.75M in profits. Earnings per share was -1.64.

In the last 12 months, operating cash flow was -17.89M and capital expenditures -49.00K, giving a free cash flow of -17.93M billion.

Aridis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Aridis Pharmaceuticals upcoming earnings date is May 20, 2025, After Close (Confirmed).

Aridis Pharmaceuticals as a current ratio of 0.32, with Debt / Equity ratio of -25.30%

In the past 12 months, Aridis Pharmaceuticals has paid 378.00K in taxes.

Aridis Pharmaceuticals EV to EBITDA ratio is -0.79, with an EV/FCF ratio of -0.80.

Aridis Pharmaceuticals has $35.00K in cash and marketable securities with $4.84M in debt, giving a net cash position of -$4.80M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Aridis Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―